Savio L. C. Woo, PhD; Alan Bernstein, PhD; Nelson A. Wivel, MD

Gene Therapy in the 21st century; Ethical considerations of the replication of genes in therapy; Diseases currently in treatment.

Richard G. Fiscella, RPh, MPH; Richard A. Quinones, MD; Bruce I. Gaynes, OD, MS, PharmD

Define glaucoma and explain disease manifestation; List different treatment options available; Describe the traditional medical treatments available; Understand the new medical agents available and how they may change therapeutic options for the treatment of glaucoma.

Health Outcomes Research

Barry Kass, RPh, MBA; Judith Barr, ScD; Gerald E. Schumacher, PharmD, PhD

This program provides an introduction to health outcomes research with an examination of the links among structure, process, and outcomes in clinical interventions and health delivery systems. System-based and patient-centered outcomes will be discussed with administrative, clinical and economic examples drawn from therapeutic drug monitoring, DUR/DUE, and other pharmacy-related topics.

Evaluation and Utilization of Pharmacoeconomic Research

Thomas O'Conner, PharmD, MBA; Michael A. Mancano, PharmD; Barbara Goppold, RPh

Identify the four basic types of pharmacoeconomic analyses; Discuss and categorize the types of relevant costs; Evaluate the criteria for a well designed pharmacoeconomic study; Interpret study results; Suggest the most appropriate treatment modality based upon study results; Identify the potential value and uses of pharmacoeconomic research in the managed care environment.

Psychiatry Update: Panic Disorder

S.A. Saeed, MD; William C. Sanderson, PhD

Treatment of Panic Disorder and Diagnosis of Panic Disorder.

The Pharmacist’s Role in Optimizing Patient Compliance

Thomas O'Conner, PharmD, MBA; Elaine D. Mackowiak, PhD; Robert S. Thompson, PhD

Patient Non-Compliance, A Major Obstacle to Improving Health Care Outcomes; Counseling and Reinforcing Proper Self-Medication; Compliance Devices.

Role of the Pharmacist in Compliance Enhancement

Mickey Smith, RPh, PhD; Jack Fincham, RPh, PhD; J. Lyle Bootman, RPh, PhD; Kent Summers, RPh, PhD; Albert I. Wertheimer, RPh, PhD

Describes the methods of detecting and predicting non-compliance, identifies the economic consequences of non-compliance to healthcare generally and in pharmacy practice, and discusses how to choose interventions best suited to enhance compliance.

Advances in Managing & Treating Attention Deficit Disorder

Joseph P. Horrigan, MD; L. Jarrett Barnhill, Jr., MD; William Lord Coleman, MD

Attention Deficit Hyperactivity Disorder Throughout the Life Cycle; Psychiatric Comorbidity; The Impact of Attention Deficit on Learning.

Current Concepts in Hypertension Management

(No Description Available.)

Managing Hyperlipidemia to Meet Patient Care Needs

Bogomir M. Kuhar, PharmD; Jean-Venable "Kelly" R. Goode, PharmD, BCPS; Kim Malone, BS

Describe current rationale and epidemiology of cholesterol management. Review cardiovascular risk factors and current NCEP guidelines for treatment. List treatment approaches to achieving NCEP goals. List drug strategies and the major adverse reactions in treating hyperlipidemia. List the benefits of a pharmacy-based lipid screening and monitoring program. Explain procedures necessary for making a hyperlipidemia clinic. Identify the strategies needed to implement & keep a pharmacy-based clinic. Develop a marketing plan for a pharmacy-based clinic.

Using Claims Data in HMO to Assess Medication Usage Emphasizing Appropriate Prescribing

Edward P. Armstrong, PharmD; Frederick Pfeiffer, RPh, MS, PharmD; Tim Sawyers, RPh, MBA, CDE;

Provide information for using claims data to assess drug therapy; Analyze claims data to determine non-adherence to chronic medications; Understand how to access medical and pharmacy claims; Differentiate medical from pharmacy claims data and report generation; Identify specific depressions management problems in a managed care setting.

Therapeutic Noncompliance in Medication Usage

Frederick Pfeiffer, PharmD; Richard Herrier, PharmD, CPE

Assess the impact of medication nonadherance to the overall cost of healthcare in the US; Determine the need for patient education regarding medications for hypertension as it relates to drug defaulting; Determine the role of common annoying side effects with diuretics in the perpetuation of therapeutic nonadherance; Describe three misconceptions regarding compliance issues; List three main factors that are required for optimal patient compliance.

Pharmacy Compounding

Art Matthys, RPh; William Letender, MS, RPh; Dave Mason, RPh; Loyd Allen, PhD

Define the terms pharmacy, manufacturing, compounding, and triad; Identify areas where pharmacists can solve non-compliance problems using compounding services; List the unique dosage forms that are available to healthcare professionals. Understand how pharmacists meet the unique needs of patients at their practice sites; List the factors that exempt pharmacists from the Federal Food and Drug and Cosmetic Act; Realize the value of compounding services in terms of patient compliance and patient needs. Identify areas of practice could potentially benefit compounding; Select a course of action to take when filling a compounded prescription .

Advances in Treating Social Phobia

Atezaz Saeed, MD; Timothy Bruce, PhD

Recognize and formally diagnose social phobia using DSM-IV; Differentiate social phobia from other primary and secondary anxiety disorders; Identify the disorders which tend to be commonly comorbid with social phobia; understand indications for drug therapy, cognitive behavior therapy, and combined treatment for social phobia; Describe classes of drugs most appropriate in treatment and first line treatments and follow-up treatment in case of non-response.

A Closer Look at the Diagnosis & Treatment of Schizophrenia

Mark D. Watanabe, PharmD, PhD; S. Charles Schulz, MD; Peter F. Buckley, MD

Define the demographic characteristics of schizophrenia; Appreciate the core diagnostic features of schizophrenia; Discuss which conditions mimic the presentation of schizophrenia; Understand the role of ancillary tests and other information in differentiating schizophrenia from neurological conditions; Identify new drugs available for full syndrome of schizophrenia; Distinguish the difference between the effects of traditional drugs and new drugs; Describe the current theories proposed for the pathogenesis of schizophrenia and their implications for rational drug therapy.